Skip to main content

Advertisement

Table 1 Characteristics of the included studies

From: A meta-analysis of serum osteocalcin level in postmenopausal osteoporotic women compared to controls

StudyCountryRegionSample sizeAge (years)aManufacturer of the OC assay kitTargetbSampling conditionNOSc
PMOControlPMOControl
Zhang 2015ChinaAsia2579062.73 (3.94)61.36 (3.75)RocheN-MIDNA6
Al-Daghri 2014Saudi ArabiaAsia10010050.6 (8.2)48.6 (7.3)RocheN-MIDfasting9
Jabbar 2011UKEurope18518562.06 (14.53)62.56 (13.24)RocheN-MIDfasting9
Verit 2006TurkeyEurope455555.68 (5.58)55.21 (6.21)NANAfasting7
Pouilles 2006FranceEurope6012052.2 (2.5)52.2 (2.7)RocheN-MIDfasting9
Luo 2006ChinaAsia454456.1 (4.4)55.6 (5.9)DSLintactfasting9
Duman 2004TurkeyEurope756653.16 (1.31)52.62 (1.69)NANAfasting7
Dominguez 1998SpainEurope261759 (6)56 (7)Metra Biosystemsintactfasting7
Kim 1996KoreaAsia143756.2 (1.7)55.6 (1.3)IncstarNAfasting7
Diaz 1995SpainEurope421462 (11)“paired”Cis-biointactfasting7
  1. OC osteocalcin, N-MID N-terminal midfragment of osteocalcin molecule, intact intact osteocalcin molecule, PMO postmenopausal osteoporosis, NOS Newcastle-Ottawa Scale, NA data not available. aAge is demonstrated with Mean (Standard deviation); bTarget fragment of the OC molecule; cRange: 1–9. Studies achieving six or more points are considered of high quality